CANVAS – Canagliflozin a kardiovaskulární a renální vliv u diabetes mellitus 2. Typu

VÍTOVEC, Jiří, Jindřich ŠPINAR and Lenka ŠPINAROVÁ. CANVAS – Canagliflozin a kardiovaskulární a renální vliv u diabetes mellitus 2. Typu. Kardiologická revue. Ambit Media a.s., 2019, vol. 21, No 1, p. 15 - 18. ISSN 1212-4540.

Basic information

• Original name: CANVAS – Canagliflozin a kardiovaskulární a renální vliv u diabetes mellitus 2. Typu
• Authors: VÍTOVEC, Jiří, Jindřich ŠPINAR and Lenka ŠPINAROVÁ.
• Edition: Kardiologická revue, Ambit Media a.s. 2019, 1212-4540.

Other information

• Original language: Czech
• Type of outcome: Article in a journal
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Organization unit: Faculty of Medicine
• Keywords in English: Canagliflozin; Cardiovascular and renal safety; Programme CANVAS; Type 2 diabetes mellitus

Abstract

Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that reduces glycaemia as well as blood pressure, body weight, and albuminuria in people with diabetes. The CANVAS Programme integrated data from two trials involving a total of 10,142 participants with type 2 diabetes and high cardiovascular risk. Participants in each trial were randomly assigned to receive canagliflozin or placebo and were followed for a mean of 188.2 weeks. The primary outcome was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Conclusions: In two trials involving patients with type 2 diabetes and an elevated risk of cardiovascular disease, patients treated with canagliflozin had a significantly lower risk of cardiovascular events than those who received placebo. A boundary higher risk of amputation, primarily at the level of the toe or metatarsus was observed in the study. These complications, however, were not proved in subsequent observational databases. © 2019, Ambit Media a.s.. All rights reserved.